Vividion's WRN Inhibitor VVD-214 Shows Promise for MSI-High Cancers in Journal of Medicinal Chemistry Publication
核心洞察
Vividion Therapeutics (搜索) published the discovery of VVD-214, a covalent Werner helicase (搜索) inhibitor, on the cover of Journal of Medicinal Chemistry, marking the first covalent inhibitor of this target in clinical development.
Preclinical studies demonstrated that VVD-214 was well tolerated and led to robust tumor regression in multiple patient-derived xenograft mouse models of MSI-high colorectal cancer (搜索).
The compound is currently being evaluated in a Phase I clinical trial as monotherapy and in combination with pembrolizumab for patients with MSI-high or mismatch repair deficient cancers (搜索).
Vividion Therapeutics (搜索) has achieved a significant breakthrough in targeting previously undruggable cancer proteins with the publication of its Werner helicase (搜索) (WRN (搜索)) inhibitor VVD-214 discovery on the cover of the Journal of Medicinal Chemistry. The manuscript, titled "Identification of VVD-214/RO7589831, a Clinical-Stage, Covalent Allosteric Inhibitor of WRN Helicase for the Treatment of MSI-High Cancers," validates the company's innovative chemoproteomics approach to reach challenging oncology targets.
Addressing Unmet Medical Need in MSI-High Cancers
"The discovery of VVD-214 marks a significant milestone in the development of a new class of potential therapies for MSI-high solid tumors," said Aleksandra Rizo, M.D., Ph.D., President and Chief Executive Officer of Vividion. "Patients with malignancies with high microsatellite instability (MSI) — including colorectal, endometrial, ovarian, and gastric cancers — have limited treatment options, and many ultimately relapse or become resistant to available therapies."
VVD-214 represents the first covalent inhibitor of WRN (搜索) to enter clinical development, targeting a protein that has historically been considered undruggable due to its helicase function.
Novel Mechanism of Action
VVD-214 is designed to exploit the dependency of MSI-high cancer cells on WRN (搜索)-mediated DNA repair, leading to selective tumor cell death while sparing healthy tissue. The compound works by inducing synthetic lethality in cancers with high microsatellite instability, where WRN function becomes essential for cell survival.
Researchers utilized Vividion's chemoproteomics platform to identify molecular fragments that covalently bound an allosteric pocket of WRN (搜索), effectively locking the protein into an inactive conformation. The discovery process involved iterative structure-activity relationship testing, with particular focus on optimizing the cysteine-reactive electrophile (vinyl sulfone) and the molecule's core aromatic rings.
Promising Preclinical Results
The resulting structure of VVD-214 was selected for its optimal balance of potency, selectivity, and drug-like ADME properties. In preclinical studies, VVD-214 demonstrated excellent tolerability and led to robust tumor regression in multiple patient-derived xenograft mouse models of MSI-high colorectal cancer (搜索).
"WRN (搜索) is a high-value oncology target known to induce synthetic lethality in cancers with high MSI, but as a helicase it has been extremely difficult to drug," explained Matt Patricelli, Ph.D., Chief Scientific Officer of Vividion. "This paper highlights the strength of Vividion's chemoproteomics platform at identifying selective small molecules against even the most challenging protein classes, while our medicinal chemistry expertise in covalent drug design enables us to optimize those discoveries into potent and selective therapeutic candidates."
Clinical Development Progress
VVD-214 is currently being evaluated in a Phase I clinical trial (NCT06004245) as both monotherapy and in combination with pembrolizumab for patients with MSI-high or mismatch repair deficient (dMMR) cancers. This clinical advancement represents a significant step forward for patients with these challenging malignancies.
The publication underscores Vividion's platform capabilities in addressing traditionally undruggable targets. As a wholly owned and independently operated subsidiary of Bayer AG, Vividion continues to leverage its proprietary chemoproteomic platform to advance a diversified pipeline of highly selective small molecule therapeutics targeting high-value oncology and immunology targets.